France· FR:60878038
UPLIZNA 100 mg, solution à diluer pour perfusion
A medicinal product containing inébilizumab, registered in France by AMGEN EUROPE.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- INÉBILIZUMAB
- Manufacturer
- AMGEN EUROPE
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550891483 flacons en verre de 10 mL
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Inébilizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumUplizna 100 mgAmgen Europe
- CanadaUPLIZNAAMGEN CANADA INC
- SwitzerlandUplizna 100 mg/10ml, Konzentrat zur Herstellung einer InfusionslösungAmgen Switzerland AG
- CzechiaUPLIZNAAmgen Europe B.V., Breda
- SpainUPLIZNA 100 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONAmgen Europe B.V.
- FinlandUpliznaAmgen Europe B.V.
- IrelandUplizna 100 mg concentrate for solution for infusionAmgen Europe B.V.,
- IcelandUpliznaAmgen Europe B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Uplizna
- Norway · Uplizna
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/28989015-98e9-4070-b235-46aaed03b6f7 GET /v1/drugs/28989015-98e9-4070-b235-46aaed03b6f7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "60878038",
"date_amm": "2022-04-25",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1602",
"substance": "INÉBILIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about inébilizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.